

# INCIDENCE OF LACTIC ACIDOSIS IN PATIENTS TREATED WITH METFORMIN



Merchante Andréu M, Salvador Gómez T, Allende Bandrés M, Cumbraos Sánchez MJ, Fernández Alonso E, Compaired Turlán V, Alcacera López M.A.

Hospital Pharmacy Unit, HCU Lozano Blesa. Zaragoza, Spain

## BACKGROUND

• Metformin is one of the most commonly prescribed medications for the treatment of type 2 diabetes mellitus (DM), particularly in overweight patients.

• A potential complication of metformin is the development of lactic acidosis (LA). This potential increased risk remains controversial.

• Some suggest that DM, rather than metformin may predispose patients to lactic acidosis.

• The summary describes this complication as very rare (<1/10,000 patient-years).

## • OBJECTIVE

• To evaluate the occurrence of LA in type 2 DM patients treated with metformin.

• To study the prevalence of acute renal failure in these patients and the final outcome.

## • MATERIAL AND METHOD

•Observational retrospective study in a general hospital.

Discharge certificates including codes of LA and DM (ICD -9 International Classification of Diseases) during 2013 were classified; we selected those under treatment with metformin.
Exclusion criteria: Patients in a decompensated diabetes/ketoacidosis and patients with chronic renal failure (known risk factors for LA).

## • **RESULTS**

• 126 discharge certificates coding LA, DM, and treatment with metformin were classified.

• 87 (69%) of these patients reached some exclusion criteria.

• Among the 39 remaining patients, in 14 of them "LA related to the use of metformin" was specifically described in the discharge certificate.

• Distribution in sex and age: 58% men and 81±10 years.

• 100% of the cases presented Acuted Renal Failure.

• One patient died, the rest were discharged after a 8±3 days median stay.

· According to data provided by the health service, 9,713 patients were being treated with

metformin in our area. It resulted in an incidence of 14 /10,000 patient-years, much higher than expected.

## CONCLUSION

• We found a much higher incidence of LA than that described in the bibliography.

• This potentially fatal complication should be avoided by means of <u>controlling risk</u> <u>factors.</u>

•A thorough review of all concomitant medication is essential.

• We consider <u>education of physicians and patients essential</u>, in this point, <u>pharmacists have an important role</u>.